A grocery receipt is a remarkably limited piece of paper.
It can tell you what was bought, from where, and perhaps when. It cannot tell you how every meal made afterward tasted, whether a recipe was followed, or what happened in a different kitchen.
That is not a flaw in the receipt. It is simply the boundary of the question it can answer.
A lab report deserves the same fair reading.
At Vanguard, we start with a simple question: what does this document prove? A certificate, a test result, a polished label, or a domestic address can tell you something useful. But none can tell you the whole story.
The same peptide name can appear in a research-use-only catalog, a contracted drug-development program, or a compounded preparation. Those are different lanes, with different intended uses, records, legal conditions, and evidence questions.
So, let’s follow three threads: what an RUO report tells you, who makes a compounded preparation behind the storefront, and what growing U.S. manufacturing capacity means for your testing decisions. Along the way, we’ll explain where our work fits.
1. RUO and what a report actually means
The first fork in the road is intended use.
Research-use-only, or RUO, catalog material is offered for laboratory research. A supplier may publish an identity result, a purity result, or a certificate of analysis for a lot. Those can be meaningful data points for the material submitted or sampled.
But they do not turn an RUO item into a finished medicine. They do not establish suitability for injection. And they do not create a drug-manufacturing history.
That distinction is not an indictment of research suppliers. Research materials have a real role in legitimate scientific work.
The trouble starts when a buyer asks an RUO certificate to answer a finished-product question it was never designed to answer.
Our starting point is the material, not the website category. Which lot is it? What are we measuring, and which test will answer that question?
What does that look like in practice?
A purity area-percent result is not the same thing as vial content. It does not establish the amount in every vial, and it does not substitute for a complete impurity profile or every relevant contaminant question.
An identity result asks whether the submitted sample matches the expected peptide under the method used. It does not tell you how much is in each vial.
And a result from one submitted vial does not certify every unsampled unit in a batch.
That distinction makes the report more useful, not less. You can see what was checked instead of guessing what a reassuring number might mean.
The same is true of independent testing. A carefully performed test does not confer FDA approval, validate a manufacturer’s entire process, or change a research product’s intended use. It answers the defined analytical question for the submitted sample and selected method.
The FDA’s August 24, 2026 warning letter to NuScience Peptides makes the intended-use point concrete. In that specific case, FDA described website claims, marketing alongside bacteriostatic water, and a peptide calculator as evidence of human-drug intent despite laboratory-use and not-for-human-use statements.
That was an enforcement finding about that firm and the facts FDA cited. It was not a finding that every RUO seller is unlawful.
Still, the lesson is useful: a research label is not FDA approval, and it is not permission for human use. A disclaimer alone does not settle intended use when the rest of the presentation says something different.
Now compare that with a CDMO supply relationship.
A contract development and manufacturing organization, or CDMO, works with a sponsor around a defined program, specifications, process knowledge, analytical methods, and documented transfers between stages. The product may still be in development. A CDMO name does not make a finished product FDA-approved.
But the relationship is built to carry a different kind of record.
SK pharmteco’s September 2026 announcement described a five-year U.S. investment plan of more than $200 million across small molecules and peptides. It included planned GMP kilo-scale peptide manufacturing and advanced liquid-chromatography capability.
That is an announcement about upstream drug-substance development: peptide manufacturing and purification. It is not an announcement of a sterile fill-finish line, and an announced timetable is not a guarantee that a project is completed or producing commercial material.
Why does the vocabulary matter? Because “peptide manufacturing” and “finished vial” are not interchangeable claims.
Before relying on a document, we recommend starting with four plain questions:
- What is the intended use: research, development, or a finished compounded preparation?
- Which exact lot does the document cover, and can that lot be traced to the container or shipment?
- Which attributes did the method measure, and which questions remain outside the report?
- If someone represents the material as a drug supply, what records connect drug substance, formulation, filling, and finished-batch release?
These are not accusations. They are the beginning of disciplined purchasing and quality communication.
2. Compounding and telehealth: who made what’s in the vial?
“Compounded” is often treated as though it describes an origin, a quality level, or a regulatory outcome.
It does none of those things by itself.
A compounded preparation starts with components, including a bulk drug substance where applicable, and moves through the compounder’s own process into a finished preparation. The evidence has to travel upstream and downstream.
A finished label cannot erase unanswered questions about source material. And an API document, by itself, cannot prove what happened during formulation, handling, filling, or release.
Here is a simple everyday analogy. Imagine a baker receives a sack of flour with a supplier certificate. That certificate may say something useful about the flour lot.
It does not tell you whether a particular cake was made to recipe, baked correctly, or packaged properly. For that, you need the records from the later steps too.
Peptide supply chains work the same way. An API, or active pharmaceutical ingredient, is the drug substance.
Formulation and aseptic filling come later. They turn appropriately qualified drug substance into a finished preparation, with controls intended to keep contamination out during filling.
They are not peptide synthesis.
The legal route matters as well. FDA’s 503A/503B comparison explains two different frameworks.
Qualifying 503A compounding is performed by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. It generally requires a valid prescription for an identified individual patient.
Qualifying 503B compounding occurs in an outsourcing facility and may or may not involve patient-specific prescriptions.
Here’s a key difference: when the relevant conditions are met, 503A products are exempt from current good manufacturing practice, or CGMP, requirements. 503B products do not receive that exemption.
FDA also describes distinct bulk-drug-substance requirements for the two pathways. In both, the bulk substance must be accompanied by a valid certificate of analysis and manufactured by an establishment registered with FDA; each pathway carries additional conditions.
FDA’s chart is not an exhaustive legal checklist. And a statutory pathway is not blanket permission for every peptide or every proposed copy.
One point should remain plain: compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness, or quality before they are marketed in the way it reviews approved drugs.
That is why documentation matters more, not less. Identify the actual compounder, identify the relevant lot, and ask what source and finished-product evidence is available for that particular preparation.
Origin deserves the same precision.
“Imported” is not another word for poor quality. “Domestic” is not a certificate of quality.
FDA’s Import Alert 66-80 addresses certain GLP-1 APIs offered for entry. It explains the information a foreign manufacturer may submit to seek green-list status, including lot certificates of analysis; release specifications and methods; potency and impurity information; microbial attributes for APIs intended for injectable drug products; stability protocols; method-validation reports; batch records; and investigations of out-of-specification results.
That list is a useful view of the evidence trail. It is not a universal one-page checklist for every peptide shipment, and it does not identify the API source for a particular clinic, compounder, or finished-dose manufacturer.
So the grounded question is not, “Did it cross a border?” It is, “What records accompany this actual lot, how was the supplier qualified, and what controls connect that lot to the finished preparation?”
Telehealth adds another handoff that can disappear behind a polished interface.
A consumer may see a brand, complete an intake flow, and receive a package without being told clearly who compounded the preparation or where the underlying drug substance originated. The brand may coordinate care, marketing, or fulfillment while another entity performs the compounding.
Those roles should not be collapsed into one claim.
In its March 2026 announcement of 30 warning letters to telehealth companies, FDA said the letters addressed false or misleading claims about compounded GLP-1 products. The violations FDA identified included claims implying sameness with FDA-approved products and advertising under a telehealth firm’s name or trademark in a way that obscured sourcing and implied that the telehealth company itself was the compounder.
This isn’t wordplay. Knowing who made it tells you whom to ask for the records.
A storefront may be the start of a transaction. It is not necessarily the manufacturing record.
For a clinic or med spa, that makes the next conversation much more practical:
- Which pharmacy or outsourcing facility compounded this preparation?
- Which lot or batch appears on its label and dispensing record?
- What bulk-substance documentation does the responsible compounder have?
- Does the claim describe the telehealth service, the compounder, or the manufacturer?
- What did the test measure in the sample being discussed?
Those are evidence questions, not medical advice or a recommendation to select any therapy.
3. U.S. fill-finish, API capacity, and our testing role
The United States is seeing investment in two different parts of the peptide supply chain: upstream API manufacturing and downstream sterile fill-finish capacity.
Both matter. They do different jobs.
Fill-finish is downstream work. It includes formulation, an aseptic filling environment and process, the container-closure system, and finished-batch controls that turn appropriately qualified drug substance into a finished dosage form, such as an aseptically filled vial or prefilled syringe.
It is not simply moving powder into a vial. And it is not proof that the facility synthesized the API in that vial.
Simtra’s Bloomington, Indiana expansion illustrates the downstream buildout. Simtra describes dedicated prefilled-syringe and vial suites in a 153,000-square-foot, two-story building, including two prefilled-syringe lines listed as available in 2026 and an isolator-based vial line listed as coming in 2027.
This is a sterile-injectable capacity announcement, not a peptide-only project. It doesn’t tell us where a particular customer’s peptide API was synthesized.
Upstream investment is developing in parallel.
Along with SK pharmteco’s announced planned GMP kilo-scale peptide manufacturing, CordenPharma’s September 2026 South Carolina announcement described an investment exceeding $200 million, 68,000 square feet of planned commercial manufacturing space, and peptide API capacity intended to complement the company’s Colorado operations.
These are announced investments and planned capacity. They are not proof that every future finished product will use domestic API, nor proof that a project is already producing commercial material.
And even a U.S. final filling step, on its own, does not reveal the origin or quality of the API. Conversely, an imported API is not disqualified by geography alone.
The evidence has to follow the lot through synthesis, purification, release, shipment, formulation, fill-finish, and distribution.
That brings us to our role at Vanguard.
We help you answer specific questions about the samples you send us. That is different from declaring an entire supply chain compliant.
Depending on the defined scope, our peptide-testing program can address purity, quantity, identity, and attributes that include endotoxins, bioburden, sterility, heavy metals, residual solvents, and more. Those are distinct attributes.
For example, bioburden is not sterility. A result should be read for the precise method and attribute it represents.
The right test can give you a clear answer about that sample. It cannot establish that every vial in a batch is identical, that a manufacturer operated under GMP, that a compounder met every legal condition, or that a product is FDA-approved.
Our ISO/IEC 17025 accreditation applies to specific accredited methods and matrices in our published scope. It does not apply to every test we offer or to an entire untested supply chain.
That clarity protects the meaning of the data.
For peptide vendors, it supports a better quality conversation: test the lot being discussed, then state the actual scope. For compounders and clinics, it helps separate API, component, and finished-preparation questions instead of blending them into one vague claim.
And for anyone trying to interpret a lab result, it replaces label-reading with something more useful: a defined sample, a defined method, and a defined question.
We continue investing in equipment and staff to support the growing demand for reliable testing. As more material moves through more suppliers and facilities, our focus stays on giving you clear, independent answers about the sample in front of us.
Let’s summarise what we covered.
First, an RUO label and a lab report have a defined scope. They can provide useful evidence, but they do not create FDA approval, permission for human use, or proof about every unsampled vial.
Second, compounded preparations and telehealth claims need records you can follow. Trace the lot from source material through the actual compounder instead of assuming the storefront is the maker.
Third, API manufacturing and fill-finish are different manufacturing stages. Announced U.S. capacity can be important context, but it does not replace lot-specific records or the defined analytical question we can test.
The one thing to do before you ship
Before shipping, tell us what you want to learn about your sample and which lot it’s from. We’ll help you choose the testing that answers that question.
Sources
- FDA warning letter: NuScience Peptides LLC (August 24, 2026)
- FDA: FD&C Act provisions that apply to human drug compounding (503A/503B)
- FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing
- FDA Import Alert 66-80: GLP-1 APIs
- SK pharmteco: U.S. small-molecule and peptide investment announcement
- Simtra BioPharma Solutions: Bloomington, Indiana expansion
- CordenPharma: South Carolina peptide-manufacturing expansion announcement
- Vanguard Laboratory: peptide testing